The clearest answer in HIV confirmation

Line immunoassay for the confirmation and discrimination of antibodies to HIV-1, HIV-1 group O and HIV-2 in human serum and plasma.

Features & Benefits

• All major HIV strains detectable with one strip: HIV-1, HIV-2, and HIV-1 group O
• Optimal specificity in screened-negative blood donors: 96.7% (290/300)
• High sensitivity in BBI panels
• Short and overnight procedures
• Colour-coded reagents
• Ready-to-use reagents
• Four control lines to monitor 1) non-specific reactivity, 2) sample addition,  3) and 4) colour development steps
• Fully automated strip processing possible using TENDIGO™, Auto-LIA™ 48, Auto-LiPA™ 48 or AutoBlot 3000(H)
• Objective, automated reading and interpretation of the strips possible using LiRAS® for Infectious Diseases

Background

Antibodies to human immunodeficiency virus (HIV) have been detected in most patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC), and in many asymptomatic individuals belonging to high-risk groups. Enzyme-linked immunosorbent assays (ELISA) are widely used to screen human blood and plasma samples for the presence of these HIV antibodies.

However, since false-positive reactions have frequently been observed with current ELISA tests, it is strongly recommended to confirm repeatedly reactive samples by use of other reliable techniques (such as the INNO-LIA HIV I/II Score). Recombinant proteins and synthetic peptides from HIV-1 and HIV-2, and a synthetic peptide from HIV-1 group O, are coated as discrete lines on a nylon strip with plastic backing.

The INNO-LIA HIV I/II Score assay contains sequences derived from HIV-O sequences to allow the optimal detection of infections caused by this group of viruses. To allow the broad spectrum detection of all HIV infections, the INNO-LIA HIV I/II Score assay also contains separate lines for the differentiation of HIV-1 and HIV-2 infections.

This is important, as HIV-2 is less virulent, resulting in a better prognosis for the patient.

For more information, visit Fujirebio.com.